A phase II study of Pro-NETU in patients receiving highly emetogenic chemotherapy (HEC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fosnetupitant (Primary) ; Cisplatin; Dexamethasone; Palonosetron
Indications Chemotherapy-induced nausea and vomiting
Focus Therapeutic Use
Sponsors Taiho Pharmaceutical

Most Recent Events

16 Sep 2023 Results of pooled Pooled Analysis from JapicCTI163355, JapicCTI194691 and JapicCTI194611 Studies evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase, published in the Advances in Therapy
22 Dec 2022 Status changed from active, no longer recruiting to completed.
05 Aug 2019 Results published in the Cancer.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight